Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224768 · ClinicalTrials.gov registry record
YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 158
- Enrollment target
NCT02224768 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 158 participants.
The verdict
NCT02224768 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 158 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients
Interventions
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2015-07 |
| Est. Completion | 2015-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02224768
The ClinicalTrials.gov registry entry for NCT02224768 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ipilimumab is the first listed.
NCT02224768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02224768 about?
NCT02224768 is a clinical study titled "YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey". To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients
What is the current status of trial NCT02224768?
This trial is currently completed. The enrollment target is 158 participants. The study started on 2015-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02224768?
The interventions under investigation include: Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02224768?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.